Kairos Pharma Ltd. (NYSE American: KAPA) announced that its President and Chief Scientific Officer, Neil Bhowmick, will present and moderate a discussion at the 24th Annual Discovery on Target Drug Discovery Conference, taking place September 28 to October 1 in Boston. Bhowmick will moderate a breakout session on September 30 titled “Winning the Race against Cancer Therapy Resistance,” which will focus on Kairos’ strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates. He will also deliver an oral plenary presentation on September 30 at 2:35 p.m. Eastern on KROS-101, the company’s drug candidate targeting solid tumors.
The presentation will center on KROS-101’s targeting of GITR (Glucocorticoid-Induced TNF Receptor) to increase T-cell function and expand effector T-cells with anti-tumor activity. This approach represents a novel avenue in immuno-oncology, aiming to overcome one of the most significant challenges in cancer treatment: resistance to existing therapies. By targeting GITR, Kairos hopes to boost the immune system’s ability to fight tumors, potentially offering new options for patients who have stopped responding to standard treatments.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. The upcoming presentation on KROS-101 adds to the company’s growing pipeline of innovative cancer therapies.
The Discovery on Target conference is a premier event for drug discovery professionals, bringing together experts from academia and industry to discuss the latest advances. Kairos’ participation underscores its commitment to advancing cancer research and its potential to make a meaningful impact in the field. For investors, the presentation could provide valuable insights into the company’s research direction and the potential of its drug candidates. The latest news and updates relating to KAPA are available in the company’s newsroom at https://nnw.fm/KAPA.
NetworkNewsWire (NNW), a specialized communications platform focused on financial news and content distribution, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. It delivers access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. For more information, please visit NetworkNewsWire. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
